Children in latest clinical study show significant reduction of tooth decay after treatment with vivos guides

Highlands ranch, colo., oct. 13, 2021 (globe newswire) -- vivos therapeutics, inc . (the “company” or “vivos”) (nasdaq: vvos), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (osa), today announced that results from a peer-reviewed, published study by an independent dentist found a significant reduction of tooth decay in pediatric patients after undergoing treatment using the company's fda class 1 registered vivos guide, a flexible, bpa-free base polymer intraoral device.
VVOS Ratings Summary
VVOS Quant Ranking